The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(E)-N-(4-(2-(3-bromo-4-hydroxy-5-methoxybenzylidene)hydrazinecarbonyl)phenyl)-2-chloroacetamide ID: ALA3394891
PubChem CID: 135995981
Max Phase: Preclinical
Molecular Formula: C17H15BrClN3O4
Molecular Weight: 440.68
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: COc1cc(/C=N/NC(=O)c2ccc(NC(=O)CCl)cc2)cc(Br)c1O
Standard InChI: InChI=1S/C17H15BrClN3O4/c1-26-14-7-10(6-13(18)16(14)24)9-20-22-17(25)11-2-4-12(5-3-11)21-15(23)8-19/h2-7,9,24H,8H2,1H3,(H,21,23)(H,22,25)/b20-9+
Standard InChI Key: PVPGIWTVFMFAFF-AWQFTUOYSA-N
Molfile:
RDKit 2D
26 27 0 0 0 0 0 0 0 0999 V2000
1.2990 -0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2990 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 1.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2990 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2990 -0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 -1.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0031 -3.0008 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.0432 -3.5993 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3383 -1.3500 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-2.3383 1.3500 0.0000 Br 0 0 0 0 0 0 0 0 0 0 0 0
2.5972 1.5031 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5951 3.0039 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.8933 3.7570 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.8912 5.2578 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1894 6.0109 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8509 5.8560 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.1894 7.5110 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4884 8.2610 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7875 7.5110 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7875 6.0110 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4885 5.2610 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.0888 8.2588 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
10.3875 7.5066 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.6887 8.2544 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.3854 6.3066 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
12.7271 7.6529 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
6 7 1 0
7 8 1 0
5 9 1 0
4 10 1 0
2 11 1 0
11 12 2 0
12 13 1 0
13 14 1 0
14 15 1 0
14 16 2 0
15 17 2 0
17 18 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 15 1 0
19 22 1 0
22 23 1 0
23 24 1 0
23 25 2 0
24 26 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 440.68Molecular Weight (Monoisotopic): 438.9934AlogP: 3.10#Rotatable Bonds: 6Polar Surface Area: 100.02Molecular Species: NEUTRALHBA: 5HBD: 3#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): ┄CX Acidic pKa: 8.29CX Basic pKa: 0.72CX LogP: 3.05CX LogD: 2.99Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.36Np Likeness Score: -1.38
References 1. Miknis GF, Stevens SJ, Smith LE, Ostrov DA, Churchill ME.. (2015) Development of novel Asf1-H3/H4 inhibitors., 25 (4): [PMID:25582598 ] [10.1016/j.bmcl.2014.11.067 ] 2. Miknis, Greg F; Stevens, Sarah J; Smith, Luke E; Ostrov, David A and Churchill, Mair E A. 2015-02-15 Development of novel Asf1-H3/H4 inhibitors. [PMID:25582598 ]